Data completeness
2/8 — Basic
ORETON METHYL (methyltestosterone) by Merck & Co. is clinical pharmacology estrogens: endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Approved for the: treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORETON METHYL (methyltestosterone) is an oral androgenic steroid indicated for treatment of moderate to severe vasomotor symptoms in menopausal women not adequately controlled by estrogens alone. It works by binding to androgen receptors to modulate hormone-responsive tissues and complement estrogen therapy.
Pre-Launch
Pre-launch pipeline asset with uncertain commercial trajectory; team size and resource allocation dependent on regulatory approval and market reception.
Mechanism of Action
CLINICAL PHARMACOLOGY Estrogens: Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the…
Worked on ORETON METHYL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.